BBC Russian

Ponazuril
Clinical data

Trade names	Marquis
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	Oral
ATCvet code	QP51BC04 (WHO)
Legal status
Legal status	US: ℞-only Veterinary use only
Identifiers
IUPAC name 1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione
CAS Number
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C₁₈H₁₄F₃N₃O₆S
Molar mass	457.38 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26)^N Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

Ponazuril (INN), sold by Merial, Inc.,^[1] now part of Boehringer Ingelheim,^[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.^[3]^[4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.^{[citation needed]}

References

^ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
^ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
^ "Marquis". Drugs.com.
^ Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Ponazuril

From Wikipedia, the free encyclopedia

See also

References